T T-DETECT Trademark

Trademark Overview


On Monday, June 6, 2022, a trademark application was filed for T T-DETECT with the United States Patent and Trademark Office. The USPTO has given the T T-DETECT trademark a serial number of 97444992. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Friday, March 22, 2024. This trademark is owned by Adaptive Biotechnologies Corp.. The T T-DETECT trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical assay kits comprised of diagnostic reagents and assays for medical use, namely, to detect cancer, autoimmune disease and infection; Diagnostic kits comprised of medical immunosequencing-based diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical immunosequencing assay kits comprised of diagnostic reagents and assays for medical use , namely, to detect cancer, autoimmune disease and infection; Medical immunosequencing-based assay kits comprised of medical grade reagents and sample plates for detecting cancer, autoimmune disease and infection

Providing medical diagnostic assays and diagnostic and prognostic testing for treatment purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; medical services; consulting services in the field of medical diagnostic and prognostic testing; medical diagnostic and prognostic testing services; providing medical immunosequencing-based diagnostic and prognostic testing for cancer, autoimmune disease and infection; consulting services in the field of medical immunosequencing-based testing; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services relating to the diagnosis and treatment of persons

Providing information about medical research in the field medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expression, namely, cancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fiel...
t t-detect

General Information


Serial Number97444992
Word MarkT T-DETECT
Filing DateMonday, June 6, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateFriday, March 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, August 1, 2023

Trademark Statements


Description of MarkThe mark consists of the design of 3 stylized ovals with one on top and two horizontally below with the space between them forming a stylized letter "T" and the stylized wording "T-Detect" to the right of the design.
Goods and ServicesDiagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical assay kits comprised of diagnostic reagents and assays for medical use, namely, to detect cancer, autoimmune disease and infection; Diagnostic kits comprised of medical immunosequencing-based diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, to detect cancer, autoimmune disease and infection; Medical immunosequencing assay kits comprised of diagnostic reagents and assays for medical use , namely, to detect cancer, autoimmune disease and infection; Medical immunosequencing-based assay kits comprised of medical grade reagents and sample plates for detecting cancer, autoimmune disease and infection
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesProviding medical diagnostic assays and diagnostic and prognostic testing for treatment purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals determine a patient's clinical diagnosis, the effectiveness of patient treatments, and to revise future treatments accordingly; medical services; consulting services in the field of medical diagnostic and prognostic testing; medical diagnostic and prognostic testing services; providing medical immunosequencing-based diagnostic and prognostic testing for cancer, autoimmune disease and infection; consulting services in the field of medical immunosequencing-based testing; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services relating to the diagnosis and treatment of persons
Goods and ServicesProviding information about medical research in the field medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expression, namely, cancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; medical research; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of laboratory testing, diagnostics, and pharmacogenetics; custom design and development of chemical reagents and biochemical assays; development of new technology for others in the field of immunotherapy; laboratory research in the field of immunotherapy, oncology, hematology, auto-immune disorders, and infectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services; medical laboratory immunosequencing-based services for analysis of biological samples

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 15, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, June 15, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, June 15, 2022
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAdaptive Biotechnologies Corp.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeattle, WA 98102

Party NameAdaptive Biotechnologies Corp.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98102

Trademark Events


Event DateEvent Description
Saturday, March 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 22, 2024SOU EXTENSION 1 GRANTED
Friday, March 22, 2024SOU EXTENSION 1 FILED
Friday, March 22, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, September 26, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 1, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 1, 2023PUBLISHED FOR OPPOSITION
Wednesday, July 12, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 27, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, June 23, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 22, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 22, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 22, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 22, 2023NON-FINAL ACTION E-MAILED
Wednesday, March 22, 2023NON-FINAL ACTION WRITTEN
Monday, March 20, 2023ASSIGNED TO EXAMINER
Thursday, June 16, 2022NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, June 15, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 9, 2022NEW APPLICATION ENTERED